Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 264Neoplasms 145Breast Neoplasms 137Colorectal Neoplasms 126Neoplasm Metastasis 94Prostatic Neoplasms 92Ovarian Neoplasms 91Multiple Myeloma 90Lung Neoplasms 86Squamous Cell Carcinoma of Head and Neck 62Pancreatic Neoplasms 61Recurrence 55Endometrial Neoplasms 55Small Cell Lung Carcinoma 50Melanoma 50Stomach Neoplasms 49Leukemia, Lymphocytic, Chronic, B-Cell 48Leukemia, Myeloid, Acute 45Carcinoma, Renal Cell 45Lymphoma, Non-Hodgkin 40Advanced Solid Tumors 39Triple Negative Breast Neoplasms 38Urinary Bladder Neoplasms 37Parkinson Disease 4, Autosomal Dominant Lewy Body 35Head and Neck Neoplasms 35Carcinoma, Hepatocellular 35Lymphoma, Large B-Cell, Diffuse 33Esophageal Neoplasms 31Lymphoma, Follicular 29Myasthenia Gravis 28

Interventions

trastuzumab deruxtecan 1Injections 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Unresectable Locally Recurrent Breast Cancer × 30 days × Clear all
NCT07497386 2026-05-11

A Trial of Trastuzumab Rezetecan in Unresectable Locally Recurrent/Metastatic Breast Cancer

Jiangsu HengRui Medicine Co., Ltd.

Phase 2 Recruiting
150 enrolled
Breast

Unresectable Locally Recurrent Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡